Oncology News: nccRCC Edition

Program Overview

Renal cell carcinomas (RCCs) are one of the most common urologic malignancies and, of the RCCs, heterogeneous non–clear cell RCC (nccRCC) represent ~25% of RCCs, with papillary carcinomas being the most common, followed by chromophobe subtype.  When patients present with advanced or metastatic nccRCC, the 5-year overall survival rate has been historically very low; however, there is a rapidly expanding systemic therapy landscape in this field.  In this Oncology News: nccRCC edition, Drs. Sumanta Pal and Wesley Yip will discuss the most recent data and their expert opinions regarding how to individualize surgical and systemic therapies for the treatment of advanced/metastatic nccRCC, with particular emphasis on papillary and chromophobe subtypes.   

Target Audience

This program will educate community-based medical oncologists and urologists.

Educational Objectives 

After completing this activity, the participant should be better able to:

1. Discuss the published efficacy and safety data of available and emerging systemic monotherapy and combination therapies for the treatment of ncc-metastatic RCC (mRCC), with particular emphasis on papillary and chromophobe RCC
2. Individualize treatment regimens for patients with nccmRCC, accounting for tumor-specific and patient-specific factors
3. Develop strategies to identify and manage treatment-emergent adverse events (TEAEs) associated with immuno-oncology (IO) and/or tyrosine kinase inhibitor (TKI) therapy

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Integritas Contact Information

For more information about the approval of this program, please contact Integritas at info@exchangecme.com. 

Instructions to Receive Credit

To receive credit for this activity, the participant must:

1. Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
2. Complete the Preactivity Questions.
3. Review the activity content.
4. Achieve a grade of at least 70% on the Postactivity Test Questions and complete the Evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosures of Conflicts of Interest

Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integritas are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas.  All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity, and that the activity is free of commercial bias.  

All relevant financial relationships have been mitigated. 

The faculty have the following relevant financial relationships with ineligible companies:

Sumanta K. Pal, MD, FASCO: Contracted Research: Allogene Therapeutics, Inc.; CRISPR Therapeutic AG; Eisai Co, Ltd.; Exelixis, Inc.; Genentech, Inc./F. Hoffman-La Roche Ltd.; and Pfizer Inc., all paid to institution.; Speakers’ Bureau: IntrinsiQ Specialty Solutions

Wesley Yip, MD: Nothing to disclose 

The Integritas Communications planners and managers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas does not recommend the use of any agent outside of the labeled indications.  

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.